Author: Editor

Laurence Albiges presents “Emerging Biomarkers of VEGF and mTOR Inhibitors in 2015” at the 14th International Kidney Cancer Symposium.

Daniel Y C Heng MD MPH FRCPC of the University of Calgary presents “Improving Patient Care Through Health Outcome Research in RCC” at the 14th International Kidney Cancer Symposium.

Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how lifestyle changes, such as physical activity and diet, can reduce the risk of progression of prostate cancer.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is implementing to increase conversations about physical activity between healthcare professionals and cancer patients.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer Support initiative aimed at helping cancer patients integrate physical activity into their routine.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses the results to date for Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial evaluating the utility of the Oncotype DX® Breast Cancer Assay to guide adjuvant treatment decisions in patients with ER-positive, HER2-negative, node-negative breast cancer. Promising outcomes at 5 years were reported in patients with a low Oncotype DX Recurrence Score® (RS) result, which suggests this population may be safely spared of chemotherapy. The evaluation continues in the study group comprising…

Judge Schonfeld-CEO-CureHunter Inc. presents “Speeding Drug Discovery with Computational Biology Network Graph Theory” at the 14th International Kidney Cancer Symposium.

John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.

Jeffrey Wallin, Ph.D. of Genentech presents “Opening the Floodgates to T Cells Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC” at the 14th International Kidney Cancer Symposium.

Fabian Zohren, MD PhD from Takeda presents “Inhibiting the mTOR Complex: Biology and Targets” at the 14th International Kidney Cancer Symposium.

Mark W Ball presents “Pathologic and Genomic Profiles of Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Toni Choueiri, MD Dana-Farber Cancer Institute presents “Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Michael Postow, MD from Memorial Sloan Kettering Cancer Center presents “Managing Side Effects of Immune Checkpoint Blockade” at the 14th International Kidney Cancer Symposium .

Dan George, MD Duke Cancer Institute presents “Oncolytic Viruses” at the 14th International Kidney Cancer Symposium.

David McDermott, MD of Dana Farber presents “The Really Important Questions Current Immunotherapy Trials are Not Answering” at the 14th International Kidney Cancer Symposium.

Ronit Simantov, M.D. of Pfizer Oncology presents “Optimizing Therapy of RCC through Industry-Academic Collaborations” at the 14th International Kidney Cancer Symposium.

Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents “Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial” at the 14th International Kidney Cancer Symposium.

Hans Hammers MD, PhD of Johns Hopkins presents “Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors” at the 14th International Kidney Cancer Symposium.

Charles G. Drake MD of Johns Hopkins Kimmel Cancer Center presents Combination Immunotherapeutic Strategies in RCC: Preclinical Rationale AND Clinical Experience

Gordon Freeman, PhD from the Dana-Farber Cancer Institute Harvard Medical School presents “The Biology of Checkpoint Inhibition” at the 14th International Kidney Cancer Symposium.

Moshe C. Ornstein MD MA of the Cleveland Clinic Taussig Cancer Institute presents “Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Andrew J. Armstrong MD ScM FACP of Duke Cancer Institute presents “Clinical Trials in Non-Clear Cell RCC” at the 14th International Kidney Cancer Symposium.

Jose A. Karam, MD, FACS of MD Anderson presents “RCC with Sarcomatoid Dedifferentiation: New Insights” at the 14th International Kidney Cancer Symposium.

Gabriel G. Malouf, MD, PhD of Pitie Salpetriere Hospital presents “Collecting Duct Renal Cell Carcinomas” at the 14th International Kidney Cancer Symposium.

Chad Creighton of Baylor College of Medicine presents “Papillary RCC: The Cancer Genome Atlas (TCGA)” at the 14th International Kidney Cancer Symposium.

Payal Kapur, M.D. of UT Southwestern Medical Center presents “Chromophobe Renal Cell Carcinoma: TCGA and UTSW Updates’ at the 14th International Kidney Cancer Symposium.

Eric Jonasch Professor of Medicine UT MD Anderson Cancer Center presents “VHL Syndrome and Hemangioblastoma Management” at the 14th International Kidney Cancer Symposium.

Paul Russo, MD, FACS of Cornell University presents “Partial Nephrectomy 15 YEARS OF PROGRESS” at the 14th International Kidney Cancer Symposium.

Suzanne B. Stewart-Merrill. MD presents ” Oncologic Surveillance Following Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach” at the 14th International Kidney Cancer Symposium.

Michael L. Blute Jr,. MD of the University of Wisconsin presents “Novel 3D volume analysis reveals primary tumor diameter is a poor predictor of tumor volume; does tumor burden actually predict survival after cytoreductive nephrectomy?’ at the 14th International Kidney Cancer Symposium.

Sarah P. Psutka M.D., M.Sc of Cook County, Chicago presents “Management of Local Recurrence After Radical Nephrectomy” at the 14th International Kidney Cancer Symposium.

E. Jason Abel, M.D. of the University of Wisconsin presents “Patient Selection for Surgery in RCC with Thrombus” at the 14th International Kidney Cancer Symposium.

Dipen J. Parekh, MD of the University of Miami Miller School of Medicine presents “WARMING UP TO ISCHEMIA” at the 14th International Kidney Cancer Symposium

Karim Touijer , MD, MPH from the Memorial Sloan-Kettering Cancer Center presents “Partial Nephrectomy: Does Ischemia Matter?” at the 14th International Kidney Cancer Symposium

James Porter of the Swedish Medical Center Seattle, WA presents “Minimally Invasive Lymphadenectomy for Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Steven C. Campbell, MD, PhD of The Cleveland Clinic discusses “Optimal Treatment of cT1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine discusses “Novel Imaging Techniques in RCC” at the 14th International Kidney Cancer Symposium.

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses “University of Wisconsin Madison” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

R. Houston Thompson, MD Professor of Urology Mayo Clinic discusses “Partial Nephrectomy or Ablation for Small Renal Mass” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Michael A.S. Jewett discusses “Surveillance is the Best Treatment for T1a RCC in a healthy 65 year old patient” at the Fourteenth International Kidney Cancer Symposium Miami, Florida, USA, November 6th , 2015 www.kidneycancersymposium.com

Stephen A. Boorjian, MD of the Mayo Clinic, Rochester, MN discusses ” CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Bradley C. Leibovich, MD, FACS , Mayo Clinic debates ” Renal Mass Biopsy Should Be Used Sparingly in patients with SRM” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Tony Finelli, MD, MSc, FRCSC Head, Division of Urology GU Site Lead, Princess Margaret Cancer Center debates the Pro side to “Renal Mass Biopsy Should be Used for Most SRM – PRO” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

A Ari Hakimi MD Memorial Sloan Kettering Cancer Center brings an “Update on Molecular and Genetic Characterization of RCC” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Brian R. Lane, M.D., Associate Professor, Michigan State University discusses “Improving Healthcare Delivery in Kidney Cancer” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the Bedford Hospital, Bedford, UK. The results of this study were presented at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma. This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.       update, update checkmate 067, phase 3 study, nivolumab, nivolumab plus ipilimumab, ipilimumab alone, in previously untreated advanced melanoma, advanced melanoma, ncri 2015, ncri, national cancer research institute, cancer conference

Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity the panacea?” at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Prof. Rob Coleman gives an overview of the session “This house believes we should stop focussing on the causes of breast cancer and get on with strategies to prevent the disease”, presented at the 2015 NCRI Cancer Conference. With Douglas Easton and Tim Key supporting the causes side, and Annie Anderson and Gareth Evans supporting the prevention side. The session was hosted by Prof. Rob Coleman.